| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Eurycomanone targets multiple enzymes and pathways. It inhibits the activity of phosphodiesterase and aromatase, which are involved in steroidogenesis. It induces apoptosis through the up-regulation of p53 and Bax, and down-regulation of Bcl-2. It has cytotoxic effects on cancer cells. It also possesses antimalarial and anticancer properties.
|
|---|---|
| ln Vitro |
When used in conjunction with the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX), etymone (EN) significantly increased the production of testosterone in a dose-dependent manner at doses of 0.1, 1.0, and 10.0 μM; however, testosterone production at the two lower doses was not significantly higher than when IBMX or EN were used alone, except at higher concentrations. Molecular docking analyses revealed that the enzyme's binding sites for IBMX and EN are distinct. The inhibitory effects of nifedipine, ketoconazole, or aminoglutethimide on the respective steroid oogenesis enzymes are not reversed by EN. Quassamine likewise did not respond to tamoxifen's suppression of estrogen receptors, but it did better when mestane inhibition of aromatase was used to lower the production of estrogen. The fact that EN and formestane bind to aromatase with comparable orientations and free energy binding values is further supported by molecular docking studies [1].
In vitro, Eurycomanone has cytotoxic effects on HepG2 cells and human cervical carcinoma cells by inducing apoptosis through the up-regulation of p53 and Bax, and down-regulation of Bcl-2. It inhibits the activity of phosphodiesterase and aromatase. It has antitumor, antimalarial, and anticancer properties. Quantitative IC50 values for its cytotoxic effects against specific cancer cell lines are not detailed in the publicly available sources. |
| ln Vivo |
In vivo, Eurycomanone promotes spermatogenesis by inhibiting the activity of phosphodiesterase and aromatase enzymes involved in estrogen production. It is the major quassinoid in Eurycoma longifolia root extract that increases spermatogenesis. It has potential applications in male fertility research. Detailed dose-response and pharmacokinetic data in animal models are limited.
|
| Enzyme Assay |
For cell-free assays, the inhibitory activity of Eurycomanone against phosphodiesterase and aromatase can be measured using standard enzyme activity assays with specific substrates. Phosphodiesterase activity can be assessed by measuring cAMP or cGMP hydrolysis. Aromatase activity can be assessed by measuring the conversion of androstenedione to estrone. Its apoptotic activity can be studied by measuring caspase activity using fluorogenic substrates.
|
| Cell Assay |
For in vitro cellular assays, the cytotoxic activity of Eurycomanone is assessed in cancer cell lines such as HepG2 and cervical carcinoma cells. Cells are treated with various concentrations of the compound, and cell viability is measured using MTT or SRB assays. Apoptosis is assessed by flow cytometry (Annexin V/PI staining) and by measuring p53, Bax, and Bcl-2 expression by Western blot.
|
| Animal Protocol |
For in vivo studies, Eurycomanone could be administered orally in animal models to assess its effects on spermatogenesis. Endpoints include sperm count, sperm motility, testicular weight, and serum testosterone levels. Its anticancer activity could be evaluated in mouse xenograft models.
|
| ADME/Pharmacokinetics |
Eurycomanone (CAS 84633-29-4) has a molecular weight of approximately 412.43 g/mol (exact molecular formula not specified in the provided sources). It is a quassinoid. Appearance: typically a powder. Solubility: DMSO and other organic solvents. Storage: typical for natural products (desiccated, protected from light, -20°C). Purity: typically >98% for research use.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a natural quassinoid from Eurycoma longifolia, it is generally considered to have low toxicity at moderate doses, but standard toxicological studies would be required for drug development. In vitro cytotoxicity assays in various cell lines are typically performed alongside efficacy studies.
|
| References | |
| Additional Infomation |
Reports have indicated that Tongkat Ali contains tongkatarione, and relevant data is available for reference.
Eurycomanone is a research-grade compound and is not approved for therapeutic use. It serves primarily as a pharmacological tool for studying spermatogenesis, steroidogenesis, and anticancer mechanisms. Its mechanism of action involves inhibition of phosphodiesterase and aromatase, and induction of apoptosis through p53/Bax/Bcl-2 pathways. It is a natural product from Eurycoma longifolia. No clinical trials have been reported. |
| Molecular Formula |
C₂₀H₂₄O₉
|
|---|---|
| Molecular Weight |
408.40
|
| Exact Mass |
408.142
|
| CAS # |
84633-29-4
|
| PubChem CID |
13936691
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
273-285℃ (methanol ethyl ether )
|
| LogP |
-2.8
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
29
|
| Complexity |
896
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
CC1=CC(=O)[C@H]([C@]2([C@H]1C[C@@H]3[C@]45[C@@H]2[C@]([C@@H](C(=C)[C@@]4([C@H](C(=O)O3)O)O)O)(OC5)O)C)O
|
| InChi Key |
UCUWZJWAQQRCOR-OKNZMGBLSA-N
|
| InChi Code |
InChI=1S/C20H24O9/c1-7-4-10(21)13(23)17(3)9(7)5-11-18-6-28-20(27,16(17)18)12(22)8(2)19(18,26)14(24)15(25)29-11/h4,9,11-14,16,22-24,26-27H,2,5-6H2,1,3H3/t9-,11+,12+,13+,14-,16+,17+,18+,19-,20-/m0/s1
|
| Chemical Name |
(1R,4R,5R,7R,8R,11R,13S,17S,18S,19R)-4,5,7,8,17-pentahydroxy-14,18-dimethyl-6-methylidene-3,10-dioxapentacyclo[9.8.0.01,7.04,19.013,18]nonadec-14-ene-9,16-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~16.67 mg/mL (~40.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.83 mg/mL (2.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.83 mg/mL (2.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.83 mg/mL (2.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4486 mL | 12.2429 mL | 24.4858 mL | |
| 5 mM | 0.4897 mL | 2.4486 mL | 4.8972 mL | |
| 10 mM | 0.2449 mL | 1.2243 mL | 2.4486 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
